Shomron Ben‐Horin

16.8k total citations · 2 hit papers
310 papers, 10.5k citations indexed

About

Shomron Ben‐Horin is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Shomron Ben‐Horin has authored 310 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Genetics, 148 papers in Epidemiology and 100 papers in Surgery. Recurrent topics in Shomron Ben‐Horin's work include Inflammatory Bowel Disease (208 papers), Microscopic Colitis (121 papers) and Immunodeficiency and Autoimmune Disorders (40 papers). Shomron Ben‐Horin is often cited by papers focused on Inflammatory Bowel Disease (208 papers), Microscopic Colitis (121 papers) and Immunodeficiency and Autoimmune Disorders (40 papers). Shomron Ben‐Horin collaborates with scholars based in Israel, United States and China. Shomron Ben‐Horin's co-authors include Yehuda Chowers, Uri Kopylov, Rami Eliakim, Orit Picard, Bella Ungar, Miri Yavzori, Ella Fudim, Adi Lahat, Eyal Klang and Benjamin Avidan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Shomron Ben‐Horin

287 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

2014 531 citations Geert D’Haens, Shomron Ben‐Horin et al. Gastroenterology profile →
Review article: loss of response to anti-TNF treatments in Crohn’s disease

2011 494 citations Shomron Ben‐Horin et al. Alimentary Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shomron Ben‐Horin Israel	54	6.6k	4.8k	3.2k	2.8k	1.5k	310	10.5k
Uri Kopylov Israel	49	5.9k 0.9×	4.1k 0.8×	2.0k 0.6×	2.8k 1.0×	1.7k 1.2×	277	8.6k
Édouard Louis Belgium	62	8.8k 1.3×	6.5k 1.3×	3.2k 1.0×	3.9k 1.4×	1.3k 0.8×	383	13.5k
P. Rutgeerts Belgium	51	7.5k 1.1×	5.7k 1.2×	2.1k 0.7×	3.4k 1.2×	1.2k 0.8×	189	11.0k
Maja Noman Belgium	37	7.1k 1.1×	5.6k 1.2×	2.9k 0.9×	2.2k 0.8×	737 0.5×	100	9.8k
Adam S. Cheifetz United States	49	4.9k 0.7×	3.6k 0.7×	2.3k 0.7×	1.9k 0.7×	889 0.6×	213	7.7k
Iris Dotan Israel	49	5.0k 0.8×	4.2k 0.9×	2.0k 0.6×	2.4k 0.8×	1.0k 0.7×	320	9.5k
Karel Geboes Belgium	42	4.9k 0.7×	4.4k 0.9×	1.4k 0.4×	3.0k 1.1×	1.2k 0.8×	201	9.3k
Alessandro Armuzzi Italy	52	5.8k 0.9×	4.4k 0.9×	2.1k 0.7×	3.5k 1.2×	1.3k 0.9×	435	10.4k
Gerassimos J. Mantzaris Greece	41	8.0k 1.2×	6.3k 1.3×	1.9k 0.6×	3.4k 1.2×	1.1k 0.7×	145	10.5k
Gary R. Lichtenstein United States	35	12.0k 1.8×	9.7k 2.0×	3.1k 1.0×	4.0k 1.4×	1.2k 0.8×	130	14.3k

Countries citing papers authored by Shomron Ben‐Horin

Since Specialization

Citations

This map shows the geographic impact of Shomron Ben‐Horin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shomron Ben‐Horin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shomron Ben‐Horin more than expected).

Fields of papers citing papers by Shomron Ben‐Horin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shomron Ben‐Horin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shomron Ben‐Horin. The network helps show where Shomron Ben‐Horin may publish in the future.

Co-authorship network of co-authors of Shomron Ben‐Horin

This figure shows the co-authorship network connecting the top 25 collaborators of Shomron Ben‐Horin. A scholar is included among the top collaborators of Shomron Ben‐Horin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shomron Ben‐Horin. Shomron Ben‐Horin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldman, Adam, et al.. (2025). Computer-Aided Detection Colonoscopy for Surveillance in IBD Patients: Insights from a Single-Center Experience. Inflammatory Bowel Diseases. 31(12). 3379–3384.

Kopylov, Uri, Bella Ungar, Eyal Shachar, et al.. (2025). P0509 Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn’s disease. Journal of Crohn s and Colitis. 19(Supplement_1). i1052–i1052.

Lama, Yago González, Ioannis E. Κoutroubakis, Ioannis Drygiannakis, et al.. (2024). P663 Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations– Retrospective study. Journal of Crohn s and Colitis. 18(Supplement_1). i1251–i1253.

Lahat, Adi, Bella Ungar, Hanoch Levy, et al.. (2024). P1067 Pan-enteric mucosal inflammation in CD patients treated with vedolizumab assessed by capsule endoscopy– interim results of a prospective observational study. Journal of Crohn s and Colitis. 18(Supplement_1). i1907–i1907. 1 indexed citations

Focht, Gili, Shira Greenfeld, Amir Ben‐Tov, et al.. (2024). Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort. Gastroenterology. 166(5). 815–825.e22. 5 indexed citations

Kopylov, Uri, et al.. (2024). Differences in disease characteristics and treatment exposures between paediatric and adult‐onset inflammatory bowel disease using a registry‐based cohort. Alimentary Pharmacology & Therapeutics. 60(10). 1435–1446. 7 indexed citations

Goldman, Adam, Emanuel Raschi, Amit Druyan, et al.. (2024). Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterology Journal. 13(4). 566–575. 3 indexed citations

Schreiber, Stefan, Geert D’Haens, Fraser Cummings, et al.. (2024). Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial. Digestive and Liver Disease. 56(7). 1204–1212. 2 indexed citations

D’Haens, Geert, Walter Reinisch, Stefan Schreiber, et al.. (2023). Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. Clinical Drug Investigation. 43(4). 277–288. 15 indexed citations

10.

Kopylov, Uri, Johan Burisch, Shomron Ben‐Horin, et al.. (2023). Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study. Inflammatory Bowel Diseases. 29(11). 1713–1722. 6 indexed citations

11.

Ben‐Horin, Shomron, Nir Salomon, N. Viazis, et al.. (2023). P560 Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial. Journal of Crohn s and Colitis. 17(Supplement_1). i691–i691. 2 indexed citations

12.

Albshesh, Ahmad, Marie Truyens, Stephan R. Vavricka, et al.. (2023). Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine. 12(7). 2503–2503. 4 indexed citations

13.

Schreiber, Stefan, Shomron Ben‐Horin, Rieke Alten, et al.. (2022). Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy. 39(6). 2342–2364. 22 indexed citations

14.

Taler, Michal, et al.. (2022). Keeping it simple: mental health assessment in the Gastroenterology Department – using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel. Therapeutic Advances in Gastroenterology. 15. 1088249415–1088249415. 7 indexed citations

15.

Ungar, Bella, Miri Yavzori, Ella Fudim, et al.. (2022). Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. Gut. 71(10). 1988–1997. 5 indexed citations

16.

Chen, Yujun, Ren Mao, Xiaohua Xie, et al.. (2015). Intracavitary Contrast-enhanced Ultrasonography to Detect Enterovesical Fistula in Crohn’s Disease. Gastroenterology. 150(2). 315–317. 14 indexed citations

17.

Kopylov, Uri, Shomron Ben‐Horin, Oded Zmora, Rami Eliakim, & Lior H. Katz. (2012). Anti-tumor necrosis factor and postoperative complications in Crohnʼs disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 18(12). 2404–2413. 137 indexed citations

18.

Jacob‐Hirsch, Jasmine, Helly Vernitsky, Yackov Berkun, et al.. (2010). TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function. The Journal of Immunology. 184(7). 3570–3581. 115 indexed citations

19.

Goldstein, Itamar, et al.. (2007). α1β1 Integrin+ and Regulatory Foxp3+ T Cells Constitute Two Functionally Distinct Human CD4+ T Cell Subsets Oppositely Modulated by TNFα Blockade. The Journal of Immunology. 178(1). 201–210. 31 indexed citations

20.

Goldstein, Itamar, Shomron Ben‐Horin, Jianfeng Li, et al.. (2003). Expression of the α1β1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells. Journal of Clinical Investigation. 112(9). 1444–1454. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact